nodes	percent_of_prediction	percent_of_DWPC	metapath
Betaxolol—CYP1A2—Dacarbazine—pancreatic cancer	0.113	0.22	CbGbCtD
Betaxolol—CYP1A2—Tamoxifen—pancreatic cancer	0.0896	0.175	CbGbCtD
Betaxolol—CYP1A2—Erlotinib—pancreatic cancer	0.0762	0.149	CbGbCtD
Betaxolol—CYP2D6—Tamoxifen—pancreatic cancer	0.0738	0.144	CbGbCtD
Betaxolol—CYP1A2—Fluorouracil—pancreatic cancer	0.066	0.129	CbGbCtD
Betaxolol—CYP2D6—Erlotinib—pancreatic cancer	0.0627	0.123	CbGbCtD
Betaxolol—CYP2D6—Doxorubicin—pancreatic cancer	0.031	0.0605	CbGbCtD
Betaxolol—Dermatitis—Sunitinib—pancreatic cancer	0.000279	0.000596	CcSEcCtD
Betaxolol—Upper respiratory tract infection—Epirubicin—pancreatic cancer	0.000278	0.000594	CcSEcCtD
Betaxolol—Urticaria—Fluorouracil—pancreatic cancer	0.000277	0.000593	CcSEcCtD
Betaxolol—Headache—Sunitinib—pancreatic cancer	0.000277	0.000593	CcSEcCtD
Betaxolol—Syncope—Docetaxel—pancreatic cancer	0.000277	0.000592	CcSEcCtD
Betaxolol—Asthma—Doxorubicin—pancreatic cancer	0.000277	0.000592	CcSEcCtD
Betaxolol—Influenza—Doxorubicin—pancreatic cancer	0.000277	0.000592	CcSEcCtD
Betaxolol—Dysphagia—Doxorubicin—pancreatic cancer	0.000277	0.000592	CcSEcCtD
Betaxolol—Body temperature increased—Fluorouracil—pancreatic cancer	0.000276	0.00059	CcSEcCtD
Betaxolol—Palpitations—Docetaxel—pancreatic cancer	0.000273	0.000584	CcSEcCtD
Betaxolol—Weight increased—Epirubicin—pancreatic cancer	0.000272	0.000582	CcSEcCtD
Betaxolol—Loss of consciousness—Docetaxel—pancreatic cancer	0.000271	0.000581	CcSEcCtD
Betaxolol—Weight decreased—Epirubicin—pancreatic cancer	0.00027	0.000579	CcSEcCtD
Betaxolol—Hyperglycaemia—Epirubicin—pancreatic cancer	0.00027	0.000577	CcSEcCtD
Betaxolol—Cough—Docetaxel—pancreatic cancer	0.000269	0.000576	CcSEcCtD
Betaxolol—Angina pectoris—Doxorubicin—pancreatic cancer	0.000269	0.000576	CcSEcCtD
Betaxolol—Hypersensitivity—Irinotecan—pancreatic cancer	0.000269	0.000575	CcSEcCtD
Betaxolol—Pneumonia—Epirubicin—pancreatic cancer	0.000268	0.000573	CcSEcCtD
Betaxolol—Infestation NOS—Epirubicin—pancreatic cancer	0.000267	0.00057	CcSEcCtD
Betaxolol—Infestation—Epirubicin—pancreatic cancer	0.000267	0.00057	CcSEcCtD
Betaxolol—Bronchitis—Doxorubicin—pancreatic cancer	0.000266	0.000569	CcSEcCtD
Betaxolol—Arthralgia—Docetaxel—pancreatic cancer	0.000263	0.000562	CcSEcCtD
Betaxolol—Chest pain—Docetaxel—pancreatic cancer	0.000263	0.000562	CcSEcCtD
Betaxolol—Myalgia—Docetaxel—pancreatic cancer	0.000263	0.000562	CcSEcCtD
Betaxolol—Nausea—Sunitinib—pancreatic cancer	0.000263	0.000562	CcSEcCtD
Betaxolol—Asthenia—Irinotecan—pancreatic cancer	0.000262	0.00056	CcSEcCtD
Betaxolol—Neuropathy peripheral—Epirubicin—pancreatic cancer	0.000261	0.000559	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000261	0.000559	CcSEcCtD
Betaxolol—Stomatitis—Epirubicin—pancreatic cancer	0.00026	0.000556	CcSEcCtD
Betaxolol—Conjunctivitis—Epirubicin—pancreatic cancer	0.000259	0.000554	CcSEcCtD
Betaxolol—Dysuria—Doxorubicin—pancreatic cancer	0.000259	0.000553	CcSEcCtD
Betaxolol—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000257	0.00055	CcSEcCtD
Betaxolol—Dry mouth—Docetaxel—pancreatic cancer	0.000257	0.00055	CcSEcCtD
Betaxolol—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000257	0.00055	CcSEcCtD
Betaxolol—Sweating—Epirubicin—pancreatic cancer	0.000255	0.000547	CcSEcCtD
Betaxolol—Asthenia—Gemcitabine—pancreatic cancer	0.000255	0.000545	CcSEcCtD
Betaxolol—Confusional state—Docetaxel—pancreatic cancer	0.000254	0.000544	CcSEcCtD
Betaxolol—Oedema—Docetaxel—pancreatic cancer	0.000252	0.000539	CcSEcCtD
Betaxolol—Weight increased—Doxorubicin—pancreatic cancer	0.000252	0.000538	CcSEcCtD
Betaxolol—Epistaxis—Epirubicin—pancreatic cancer	0.000251	0.000538	CcSEcCtD
Betaxolol—Pruritus—Gemcitabine—pancreatic cancer	0.000251	0.000537	CcSEcCtD
Betaxolol—Infection—Docetaxel—pancreatic cancer	0.00025	0.000536	CcSEcCtD
Betaxolol—Weight decreased—Doxorubicin—pancreatic cancer	0.00025	0.000535	CcSEcCtD
Betaxolol—Sinusitis—Epirubicin—pancreatic cancer	0.00025	0.000535	CcSEcCtD
Betaxolol—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000249	0.000534	CcSEcCtD
Betaxolol—Diarrhoea—Irinotecan—pancreatic cancer	0.000249	0.000534	CcSEcCtD
Betaxolol—Agranulocytosis—Epirubicin—pancreatic cancer	0.000249	0.000532	CcSEcCtD
Betaxolol—Pneumonia—Doxorubicin—pancreatic cancer	0.000248	0.000531	CcSEcCtD
Betaxolol—Shock—Docetaxel—pancreatic cancer	0.000248	0.00053	CcSEcCtD
Betaxolol—Nervous system disorder—Docetaxel—pancreatic cancer	0.000247	0.000529	CcSEcCtD
Betaxolol—Pruritus—Fluorouracil—pancreatic cancer	0.000247	0.000528	CcSEcCtD
Betaxolol—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000247	0.000528	CcSEcCtD
Betaxolol—Infestation—Doxorubicin—pancreatic cancer	0.000247	0.000528	CcSEcCtD
Betaxolol—Infestation NOS—Doxorubicin—pancreatic cancer	0.000247	0.000528	CcSEcCtD
Betaxolol—Tachycardia—Docetaxel—pancreatic cancer	0.000246	0.000526	CcSEcCtD
Betaxolol—Skin disorder—Docetaxel—pancreatic cancer	0.000245	0.000524	CcSEcCtD
Betaxolol—Bradycardia—Epirubicin—pancreatic cancer	0.000244	0.000521	CcSEcCtD
Betaxolol—Diarrhoea—Gemcitabine—pancreatic cancer	0.000243	0.00052	CcSEcCtD
Betaxolol—Neuropathy peripheral—Doxorubicin—pancreatic cancer	0.000242	0.000517	CcSEcCtD
Betaxolol—Dizziness—Irinotecan—pancreatic cancer	0.000241	0.000516	CcSEcCtD
Betaxolol—Stomatitis—Doxorubicin—pancreatic cancer	0.00024	0.000514	CcSEcCtD
Betaxolol—Anorexia—Docetaxel—pancreatic cancer	0.00024	0.000514	CcSEcCtD
Betaxolol—Rhinitis—Epirubicin—pancreatic cancer	0.00024	0.000513	CcSEcCtD
Betaxolol—Conjunctivitis—Doxorubicin—pancreatic cancer	0.00024	0.000513	CcSEcCtD
Betaxolol—Diarrhoea—Fluorouracil—pancreatic cancer	0.000239	0.000511	CcSEcCtD
Betaxolol—Hypoaesthesia—Epirubicin—pancreatic cancer	0.000238	0.000509	CcSEcCtD
Betaxolol—Pharyngitis—Epirubicin—pancreatic cancer	0.000237	0.000508	CcSEcCtD
Betaxolol—Sweating—Doxorubicin—pancreatic cancer	0.000236	0.000506	CcSEcCtD
Betaxolol—Hypotension—Docetaxel—pancreatic cancer	0.000235	0.000504	CcSEcCtD
Betaxolol—Epistaxis—Doxorubicin—pancreatic cancer	0.000233	0.000498	CcSEcCtD
Betaxolol—Vomiting—Irinotecan—pancreatic cancer	0.000232	0.000496	CcSEcCtD
Betaxolol—Sinusitis—Doxorubicin—pancreatic cancer	0.000231	0.000495	CcSEcCtD
Betaxolol—Dizziness—Fluorouracil—pancreatic cancer	0.000231	0.000494	CcSEcCtD
Betaxolol—Visual impairment—Epirubicin—pancreatic cancer	0.000231	0.000493	CcSEcCtD
Betaxolol—Agranulocytosis—Doxorubicin—pancreatic cancer	0.00023	0.000492	CcSEcCtD
Betaxolol—Rash—Irinotecan—pancreatic cancer	0.00023	0.000492	CcSEcCtD
Betaxolol—Dermatitis—Irinotecan—pancreatic cancer	0.00023	0.000491	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.00023	0.000491	CcSEcCtD
Betaxolol—Headache—Irinotecan—pancreatic cancer	0.000228	0.000489	CcSEcCtD
Betaxolol—Insomnia—Docetaxel—pancreatic cancer	0.000228	0.000488	CcSEcCtD
Betaxolol—Paraesthesia—Docetaxel—pancreatic cancer	0.000226	0.000484	CcSEcCtD
Betaxolol—Vomiting—Gemcitabine—pancreatic cancer	0.000226	0.000483	CcSEcCtD
Betaxolol—Bradycardia—Doxorubicin—pancreatic cancer	0.000225	0.000482	CcSEcCtD
Betaxolol—Dyspnoea—Docetaxel—pancreatic cancer	0.000225	0.000481	CcSEcCtD
Betaxolol—Rash—Gemcitabine—pancreatic cancer	0.000224	0.000479	CcSEcCtD
Betaxolol—Dermatitis—Gemcitabine—pancreatic cancer	0.000224	0.000479	CcSEcCtD
Betaxolol—Eye disorder—Epirubicin—pancreatic cancer	0.000224	0.000478	CcSEcCtD
Betaxolol—Tinnitus—Epirubicin—pancreatic cancer	0.000223	0.000477	CcSEcCtD
Betaxolol—Headache—Gemcitabine—pancreatic cancer	0.000222	0.000476	CcSEcCtD
Betaxolol—Flushing—Epirubicin—pancreatic cancer	0.000222	0.000475	CcSEcCtD
Betaxolol—Cardiac disorder—Epirubicin—pancreatic cancer	0.000222	0.000475	CcSEcCtD
Betaxolol—Vomiting—Fluorouracil—pancreatic cancer	0.000222	0.000475	CcSEcCtD
Betaxolol—Rhinitis—Doxorubicin—pancreatic cancer	0.000222	0.000475	CcSEcCtD
Betaxolol—Dyspepsia—Docetaxel—pancreatic cancer	0.000222	0.000475	CcSEcCtD
Betaxolol—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.00022	0.000471	CcSEcCtD
Betaxolol—Rash—Fluorouracil—pancreatic cancer	0.00022	0.000471	CcSEcCtD
Betaxolol—Dermatitis—Fluorouracil—pancreatic cancer	0.00022	0.000471	CcSEcCtD
Betaxolol—Pharyngitis—Doxorubicin—pancreatic cancer	0.00022	0.00047	CcSEcCtD
Betaxolol—Decreased appetite—Docetaxel—pancreatic cancer	0.000219	0.000469	CcSEcCtD
Betaxolol—Headache—Fluorouracil—pancreatic cancer	0.000219	0.000468	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000218	0.000465	CcSEcCtD
Betaxolol—Fatigue—Docetaxel—pancreatic cancer	0.000217	0.000465	CcSEcCtD
Betaxolol—Angiopathy—Epirubicin—pancreatic cancer	0.000217	0.000464	CcSEcCtD
Betaxolol—Nausea—Irinotecan—pancreatic cancer	0.000217	0.000463	CcSEcCtD
Betaxolol—Immune system disorder—Epirubicin—pancreatic cancer	0.000216	0.000462	CcSEcCtD
Betaxolol—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000216	0.000461	CcSEcCtD
Betaxolol—Constipation—Docetaxel—pancreatic cancer	0.000215	0.000461	CcSEcCtD
Betaxolol—Pain—Docetaxel—pancreatic cancer	0.000215	0.000461	CcSEcCtD
Betaxolol—Chills—Epirubicin—pancreatic cancer	0.000215	0.000459	CcSEcCtD
Betaxolol—Arrhythmia—Epirubicin—pancreatic cancer	0.000214	0.000457	CcSEcCtD
Betaxolol—Visual impairment—Doxorubicin—pancreatic cancer	0.000213	0.000456	CcSEcCtD
Betaxolol—Alopecia—Epirubicin—pancreatic cancer	0.000211	0.000452	CcSEcCtD
Betaxolol—Nausea—Gemcitabine—pancreatic cancer	0.000211	0.000451	CcSEcCtD
Betaxolol—Mental disorder—Epirubicin—pancreatic cancer	0.00021	0.000448	CcSEcCtD
Betaxolol—Malnutrition—Epirubicin—pancreatic cancer	0.000208	0.000446	CcSEcCtD
Betaxolol—Erythema—Epirubicin—pancreatic cancer	0.000208	0.000446	CcSEcCtD
Betaxolol—Feeling abnormal—Docetaxel—pancreatic cancer	0.000208	0.000444	CcSEcCtD
Betaxolol—Nausea—Fluorouracil—pancreatic cancer	0.000207	0.000444	CcSEcCtD
Betaxolol—Eye disorder—Doxorubicin—pancreatic cancer	0.000207	0.000443	CcSEcCtD
Betaxolol—Tinnitus—Doxorubicin—pancreatic cancer	0.000206	0.000442	CcSEcCtD
Betaxolol—Flushing—Doxorubicin—pancreatic cancer	0.000205	0.00044	CcSEcCtD
Betaxolol—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000205	0.00044	CcSEcCtD
Betaxolol—Tension—Epirubicin—pancreatic cancer	0.000204	0.000437	CcSEcCtD
Betaxolol—Dysgeusia—Epirubicin—pancreatic cancer	0.000204	0.000436	CcSEcCtD
Betaxolol—Nervousness—Epirubicin—pancreatic cancer	0.000202	0.000433	CcSEcCtD
Betaxolol—Angiopathy—Doxorubicin—pancreatic cancer	0.000201	0.00043	CcSEcCtD
Betaxolol—Muscle spasms—Epirubicin—pancreatic cancer	0.0002	0.000428	CcSEcCtD
Betaxolol—Immune system disorder—Doxorubicin—pancreatic cancer	0.0002	0.000428	CcSEcCtD
Betaxolol—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.0002	0.000427	CcSEcCtD
Betaxolol—Body temperature increased—Docetaxel—pancreatic cancer	0.000199	0.000426	CcSEcCtD
Betaxolol—Chills—Doxorubicin—pancreatic cancer	0.000199	0.000425	CcSEcCtD
Betaxolol—Arrhythmia—Doxorubicin—pancreatic cancer	0.000198	0.000423	CcSEcCtD
Betaxolol—Vision blurred—Epirubicin—pancreatic cancer	0.000196	0.00042	CcSEcCtD
Betaxolol—Alopecia—Doxorubicin—pancreatic cancer	0.000196	0.000419	CcSEcCtD
Betaxolol—Mental disorder—Doxorubicin—pancreatic cancer	0.000194	0.000415	CcSEcCtD
Betaxolol—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000193	0.000413	CcSEcCtD
Betaxolol—Erythema—Doxorubicin—pancreatic cancer	0.000193	0.000412	CcSEcCtD
Betaxolol—Malnutrition—Doxorubicin—pancreatic cancer	0.000193	0.000412	CcSEcCtD
Betaxolol—Anaemia—Epirubicin—pancreatic cancer	0.000192	0.000412	CcSEcCtD
Betaxolol—Tension—Doxorubicin—pancreatic cancer	0.000189	0.000405	CcSEcCtD
Betaxolol—Dysgeusia—Doxorubicin—pancreatic cancer	0.000189	0.000404	CcSEcCtD
Betaxolol—Malaise—Epirubicin—pancreatic cancer	0.000188	0.000402	CcSEcCtD
Betaxolol—Nervousness—Doxorubicin—pancreatic cancer	0.000187	0.0004	CcSEcCtD
Betaxolol—Vertigo—Epirubicin—pancreatic cancer	0.000187	0.0004	CcSEcCtD
Betaxolol—Syncope—Epirubicin—pancreatic cancer	0.000187	0.0004	CcSEcCtD
Betaxolol—Hypersensitivity—Docetaxel—pancreatic cancer	0.000186	0.000397	CcSEcCtD
Betaxolol—Muscle spasms—Doxorubicin—pancreatic cancer	0.000185	0.000396	CcSEcCtD
Betaxolol—Palpitations—Epirubicin—pancreatic cancer	0.000184	0.000394	CcSEcCtD
Betaxolol—Loss of consciousness—Epirubicin—pancreatic cancer	0.000183	0.000392	CcSEcCtD
Betaxolol—Cough—Epirubicin—pancreatic cancer	0.000182	0.000389	CcSEcCtD
Betaxolol—Vision blurred—Doxorubicin—pancreatic cancer	0.000182	0.000389	CcSEcCtD
Betaxolol—Asthenia—Docetaxel—pancreatic cancer	0.000181	0.000387	CcSEcCtD
Betaxolol—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000179	0.000383	CcSEcCtD
Betaxolol—Pruritus—Docetaxel—pancreatic cancer	0.000178	0.000381	CcSEcCtD
Betaxolol—Anaemia—Doxorubicin—pancreatic cancer	0.000178	0.000381	CcSEcCtD
Betaxolol—Myalgia—Epirubicin—pancreatic cancer	0.000177	0.000379	CcSEcCtD
Betaxolol—Chest pain—Epirubicin—pancreatic cancer	0.000177	0.000379	CcSEcCtD
Betaxolol—Arthralgia—Epirubicin—pancreatic cancer	0.000177	0.000379	CcSEcCtD
Betaxolol—Anxiety—Epirubicin—pancreatic cancer	0.000177	0.000378	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000176	0.000377	CcSEcCtD
Betaxolol—Discomfort—Epirubicin—pancreatic cancer	0.000175	0.000375	CcSEcCtD
Betaxolol—Malaise—Doxorubicin—pancreatic cancer	0.000174	0.000372	CcSEcCtD
Betaxolol—Dry mouth—Epirubicin—pancreatic cancer	0.000173	0.000371	CcSEcCtD
Betaxolol—Vertigo—Doxorubicin—pancreatic cancer	0.000173	0.00037	CcSEcCtD
Betaxolol—Syncope—Doxorubicin—pancreatic cancer	0.000173	0.00037	CcSEcCtD
Betaxolol—Diarrhoea—Docetaxel—pancreatic cancer	0.000172	0.000369	CcSEcCtD
Betaxolol—Confusional state—Epirubicin—pancreatic cancer	0.000171	0.000367	CcSEcCtD
Betaxolol—Palpitations—Doxorubicin—pancreatic cancer	0.00017	0.000364	CcSEcCtD
Betaxolol—Oedema—Epirubicin—pancreatic cancer	0.00017	0.000364	CcSEcCtD
Betaxolol—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000169	0.000362	CcSEcCtD
Betaxolol—Infection—Epirubicin—pancreatic cancer	0.000169	0.000361	CcSEcCtD
Betaxolol—Cough—Doxorubicin—pancreatic cancer	0.000168	0.00036	CcSEcCtD
Betaxolol—Shock—Epirubicin—pancreatic cancer	0.000167	0.000358	CcSEcCtD
Betaxolol—Nervous system disorder—Epirubicin—pancreatic cancer	0.000167	0.000357	CcSEcCtD
Betaxolol—Dizziness—Docetaxel—pancreatic cancer	0.000167	0.000357	CcSEcCtD
Betaxolol—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000166	0.000356	CcSEcCtD
Betaxolol—Tachycardia—Epirubicin—pancreatic cancer	0.000166	0.000355	CcSEcCtD
Betaxolol—Skin disorder—Epirubicin—pancreatic cancer	0.000165	0.000353	CcSEcCtD
Betaxolol—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000164	0.000352	CcSEcCtD
Betaxolol—Myalgia—Doxorubicin—pancreatic cancer	0.000164	0.000351	CcSEcCtD
Betaxolol—Arthralgia—Doxorubicin—pancreatic cancer	0.000164	0.000351	CcSEcCtD
Betaxolol—Chest pain—Doxorubicin—pancreatic cancer	0.000164	0.000351	CcSEcCtD
Betaxolol—Anxiety—Doxorubicin—pancreatic cancer	0.000163	0.00035	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000163	0.000349	CcSEcCtD
Betaxolol—Discomfort—Doxorubicin—pancreatic cancer	0.000162	0.000347	CcSEcCtD
Betaxolol—Anorexia—Epirubicin—pancreatic cancer	0.000162	0.000347	CcSEcCtD
Betaxolol—Dry mouth—Doxorubicin—pancreatic cancer	0.00016	0.000343	CcSEcCtD
Betaxolol—Vomiting—Docetaxel—pancreatic cancer	0.00016	0.000343	CcSEcCtD
Betaxolol—Rash—Docetaxel—pancreatic cancer	0.000159	0.00034	CcSEcCtD
Betaxolol—Hypotension—Epirubicin—pancreatic cancer	0.000159	0.00034	CcSEcCtD
Betaxolol—Dermatitis—Docetaxel—pancreatic cancer	0.000159	0.00034	CcSEcCtD
Betaxolol—Confusional state—Doxorubicin—pancreatic cancer	0.000159	0.000339	CcSEcCtD
Betaxolol—Headache—Docetaxel—pancreatic cancer	0.000158	0.000338	CcSEcCtD
Betaxolol—Oedema—Doxorubicin—pancreatic cancer	0.000157	0.000336	CcSEcCtD
Betaxolol—Infection—Doxorubicin—pancreatic cancer	0.000156	0.000334	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000155	0.000331	CcSEcCtD
Betaxolol—Shock—Doxorubicin—pancreatic cancer	0.000155	0.000331	CcSEcCtD
Betaxolol—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000154	0.00033	CcSEcCtD
Betaxolol—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000154	0.000329	CcSEcCtD
Betaxolol—Insomnia—Epirubicin—pancreatic cancer	0.000154	0.000329	CcSEcCtD
Betaxolol—Tachycardia—Doxorubicin—pancreatic cancer	0.000153	0.000328	CcSEcCtD
Betaxolol—Skin disorder—Doxorubicin—pancreatic cancer	0.000153	0.000327	CcSEcCtD
Betaxolol—Paraesthesia—Epirubicin—pancreatic cancer	0.000153	0.000327	CcSEcCtD
Betaxolol—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000152	0.000325	CcSEcCtD
Betaxolol—Dyspnoea—Epirubicin—pancreatic cancer	0.000152	0.000324	CcSEcCtD
Betaxolol—Anorexia—Doxorubicin—pancreatic cancer	0.00015	0.000321	CcSEcCtD
Betaxolol—Nausea—Docetaxel—pancreatic cancer	0.00015	0.00032	CcSEcCtD
Betaxolol—Dyspepsia—Epirubicin—pancreatic cancer	0.00015	0.00032	CcSEcCtD
Betaxolol—Decreased appetite—Epirubicin—pancreatic cancer	0.000148	0.000316	CcSEcCtD
Betaxolol—Hypotension—Doxorubicin—pancreatic cancer	0.000147	0.000314	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000147	0.000314	CcSEcCtD
Betaxolol—Fatigue—Epirubicin—pancreatic cancer	0.000147	0.000314	CcSEcCtD
Betaxolol—Pain—Epirubicin—pancreatic cancer	0.000145	0.000311	CcSEcCtD
Betaxolol—Constipation—Epirubicin—pancreatic cancer	0.000145	0.000311	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000143	0.000307	CcSEcCtD
Betaxolol—Insomnia—Doxorubicin—pancreatic cancer	0.000142	0.000304	CcSEcCtD
Betaxolol—Paraesthesia—Doxorubicin—pancreatic cancer	0.000141	0.000302	CcSEcCtD
Betaxolol—Dyspnoea—Doxorubicin—pancreatic cancer	0.00014	0.0003	CcSEcCtD
Betaxolol—Feeling abnormal—Epirubicin—pancreatic cancer	0.00014	0.0003	CcSEcCtD
Betaxolol—Dyspepsia—Doxorubicin—pancreatic cancer	0.000138	0.000296	CcSEcCtD
Betaxolol—Decreased appetite—Doxorubicin—pancreatic cancer	0.000137	0.000292	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000136	0.00029	CcSEcCtD
Betaxolol—Fatigue—Doxorubicin—pancreatic cancer	0.000136	0.00029	CcSEcCtD
Betaxolol—Urticaria—Epirubicin—pancreatic cancer	0.000135	0.000289	CcSEcCtD
Betaxolol—Pain—Doxorubicin—pancreatic cancer	0.000134	0.000288	CcSEcCtD
Betaxolol—Constipation—Doxorubicin—pancreatic cancer	0.000134	0.000288	CcSEcCtD
Betaxolol—Body temperature increased—Epirubicin—pancreatic cancer	0.000134	0.000287	CcSEcCtD
Betaxolol—Feeling abnormal—Doxorubicin—pancreatic cancer	0.00013	0.000277	CcSEcCtD
Betaxolol—Hypersensitivity—Epirubicin—pancreatic cancer	0.000125	0.000268	CcSEcCtD
Betaxolol—Urticaria—Doxorubicin—pancreatic cancer	0.000125	0.000267	CcSEcCtD
Betaxolol—Body temperature increased—Doxorubicin—pancreatic cancer	0.000124	0.000266	CcSEcCtD
Betaxolol—Asthenia—Epirubicin—pancreatic cancer	0.000122	0.000261	CcSEcCtD
Betaxolol—Pruritus—Epirubicin—pancreatic cancer	0.00012	0.000257	CcSEcCtD
Betaxolol—Diarrhoea—Epirubicin—pancreatic cancer	0.000116	0.000249	CcSEcCtD
Betaxolol—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000116	0.000248	CcSEcCtD
Betaxolol—Asthenia—Doxorubicin—pancreatic cancer	0.000113	0.000241	CcSEcCtD
Betaxolol—Dizziness—Epirubicin—pancreatic cancer	0.000112	0.00024	CcSEcCtD
Betaxolol—Pruritus—Doxorubicin—pancreatic cancer	0.000111	0.000238	CcSEcCtD
Betaxolol—Vomiting—Epirubicin—pancreatic cancer	0.000108	0.000231	CcSEcCtD
Betaxolol—Diarrhoea—Doxorubicin—pancreatic cancer	0.000108	0.00023	CcSEcCtD
Betaxolol—Rash—Epirubicin—pancreatic cancer	0.000107	0.000229	CcSEcCtD
Betaxolol—Dermatitis—Epirubicin—pancreatic cancer	0.000107	0.000229	CcSEcCtD
Betaxolol—Headache—Epirubicin—pancreatic cancer	0.000106	0.000228	CcSEcCtD
Betaxolol—Dizziness—Doxorubicin—pancreatic cancer	0.000104	0.000223	CcSEcCtD
Betaxolol—Nausea—Epirubicin—pancreatic cancer	0.000101	0.000216	CcSEcCtD
Betaxolol—Vomiting—Doxorubicin—pancreatic cancer	0.0001	0.000214	CcSEcCtD
Betaxolol—Rash—Doxorubicin—pancreatic cancer	9.92e-05	0.000212	CcSEcCtD
Betaxolol—Dermatitis—Doxorubicin—pancreatic cancer	9.91e-05	0.000212	CcSEcCtD
Betaxolol—Headache—Doxorubicin—pancreatic cancer	9.85e-05	0.000211	CcSEcCtD
Betaxolol—Nausea—Doxorubicin—pancreatic cancer	9.34e-05	0.0002	CcSEcCtD
Betaxolol—ADRB1—Signaling by GPCR—CCK—pancreatic cancer	3.88e-05	0.00186	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PRLHR—pancreatic cancer	3.81e-05	0.00182	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—CCK—pancreatic cancer	3.8e-05	0.00182	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—CNR2—pancreatic cancer	3.78e-05	0.00181	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—GLP1R—pancreatic cancer	3.78e-05	0.00181	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—CCKAR—pancreatic cancer	3.72e-05	0.00178	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—CNR2—pancreatic cancer	3.7e-05	0.00177	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—GLP1R—pancreatic cancer	3.7e-05	0.00177	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—IAPP—pancreatic cancer	3.69e-05	0.00177	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—ACVR1B—pancreatic cancer	3.66e-05	0.00175	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—ZNRF3—pancreatic cancer	3.66e-05	0.00175	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—CCKAR—pancreatic cancer	3.64e-05	0.00174	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—IAPP—pancreatic cancer	3.61e-05	0.00173	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—ZNRF3—pancreatic cancer	3.58e-05	0.00171	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—ACVR1B—pancreatic cancer	3.58e-05	0.00171	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—PTHLH—pancreatic cancer	3.54e-05	0.0017	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—PTHLH—pancreatic cancer	3.47e-05	0.00166	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—SHH—pancreatic cancer	3.39e-05	0.00163	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—IAPP—pancreatic cancer	3.35e-05	0.00161	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—SHH—pancreatic cancer	3.32e-05	0.00159	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—pancreatic cancer	3.31e-05	0.00159	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—SSTR3—pancreatic cancer	3.31e-05	0.00158	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—DTX1—pancreatic cancer	3.31e-05	0.00158	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—IAPP—pancreatic cancer	3.28e-05	0.00157	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—SST—pancreatic cancer	3.24e-05	0.00155	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—SSTR3—pancreatic cancer	3.24e-05	0.00155	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—DTX1—pancreatic cancer	3.24e-05	0.00155	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—PTCH1—pancreatic cancer	3.22e-05	0.00154	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—PTHLH—pancreatic cancer	3.22e-05	0.00154	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—SSTR1—pancreatic cancer	3.17e-05	0.00152	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—SST—pancreatic cancer	3.17e-05	0.00152	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—PTHLH—pancreatic cancer	3.15e-05	0.00151	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—PTCH1—pancreatic cancer	3.15e-05	0.00151	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PPY—pancreatic cancer	3.11e-05	0.00149	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—SSTR1—pancreatic cancer	3.1e-05	0.00149	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—SSTR2—pancreatic cancer	3.05e-05	0.00146	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PPY—pancreatic cancer	3.04e-05	0.00146	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—CNR1—pancreatic cancer	2.99e-05	0.00143	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—SSTR2—pancreatic cancer	2.99e-05	0.00143	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CCKBR—pancreatic cancer	2.95e-05	0.00141	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—SST—pancreatic cancer	2.94e-05	0.00141	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	2.93e-05	0.0014	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—CNR1—pancreatic cancer	2.93e-05	0.0014	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—GCG—pancreatic cancer	2.89e-05	0.00138	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CCKBR—pancreatic cancer	2.89e-05	0.00138	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—SST—pancreatic cancer	2.88e-05	0.00138	CbGpPWpGaD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	2.87e-05	0.00137	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—GCG—pancreatic cancer	2.83e-05	0.00135	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—DTX4—pancreatic cancer	2.77e-05	0.00133	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—GLI1—pancreatic cancer	2.77e-05	0.00133	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—AGTR1—pancreatic cancer	2.76e-05	0.00132	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—CNR1—pancreatic cancer	2.72e-05	0.0013	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—DTX4—pancreatic cancer	2.71e-05	0.0013	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—GLI1—pancreatic cancer	2.71e-05	0.0013	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PPP2R5B—pancreatic cancer	2.7e-05	0.00129	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—NRP1—pancreatic cancer	2.7e-05	0.00129	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—AGTR1—pancreatic cancer	2.7e-05	0.00129	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—CNR1—pancreatic cancer	2.66e-05	0.00127	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—NRP1—pancreatic cancer	2.64e-05	0.00126	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PPP2R5B—pancreatic cancer	2.64e-05	0.00126	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—GCG—pancreatic cancer	2.62e-05	0.00126	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—HEY2—pancreatic cancer	2.6e-05	0.00124	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—GCG—pancreatic cancer	2.57e-05	0.00123	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—HEY2—pancreatic cancer	2.54e-05	0.00122	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—GAST—pancreatic cancer	2.54e-05	0.00121	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—AGTR1—pancreatic cancer	2.5e-05	0.0012	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—GAST—pancreatic cancer	2.48e-05	0.00119	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—AGTR1—pancreatic cancer	2.45e-05	0.00117	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—SCT—pancreatic cancer	2.4e-05	0.00115	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—HEY1—pancreatic cancer	2.4e-05	0.00115	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—HEY1—pancreatic cancer	2.35e-05	0.00113	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—SCT—pancreatic cancer	2.35e-05	0.00113	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CCK—pancreatic cancer	2.29e-05	0.0011	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CCK—pancreatic cancer	2.24e-05	0.00107	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CNR2—pancreatic cancer	2.24e-05	0.00107	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—GLP1R—pancreatic cancer	2.24e-05	0.00107	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—CXCL8—pancreatic cancer	2.23e-05	0.00107	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CCKAR—pancreatic cancer	2.2e-05	0.00105	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CNR2—pancreatic cancer	2.19e-05	0.00105	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—GLP1R—pancreatic cancer	2.19e-05	0.00105	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—CXCL8—pancreatic cancer	2.19e-05	0.00105	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CCKAR—pancreatic cancer	2.15e-05	0.00103	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PRSS1—pancreatic cancer	2.14e-05	0.00103	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—JAG2—pancreatic cancer	2.13e-05	0.00102	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MEN1—pancreatic cancer	2.1e-05	0.00101	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—JAG2—pancreatic cancer	2.09e-05	0.000999	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MEN1—pancreatic cancer	2.06e-05	0.000985	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—SHH—pancreatic cancer	2.01e-05	0.00096	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—NOTCH4—pancreatic cancer	1.99e-05	0.000954	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—IAPP—pancreatic cancer	1.98e-05	0.000948	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—SHH—pancreatic cancer	1.96e-05	0.000939	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—NOTCH4—pancreatic cancer	1.95e-05	0.000933	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—IAPP—pancreatic cancer	1.94e-05	0.000928	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PTHLH—pancreatic cancer	1.9e-05	0.00091	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PTCH1—pancreatic cancer	1.9e-05	0.00091	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PTHLH—pancreatic cancer	1.86e-05	0.00089	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PTCH1—pancreatic cancer	1.86e-05	0.00089	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ARG2—pancreatic cancer	1.86e-05	0.00089	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PRSS1—pancreatic cancer	1.82e-05	0.00087	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—SST—pancreatic cancer	1.74e-05	0.000832	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—PIK3CG—pancreatic cancer	1.71e-05	0.000821	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—JAG1—pancreatic cancer	1.7e-05	0.000815	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—SST—pancreatic cancer	1.7e-05	0.000814	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—NOTCH3—pancreatic cancer	1.69e-05	0.000811	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—PIK3CG—pancreatic cancer	1.68e-05	0.000803	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—JAG1—pancreatic cancer	1.66e-05	0.000797	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—NOTCH3—pancreatic cancer	1.66e-05	0.000794	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—TYMP—pancreatic cancer	1.62e-05	0.000778	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CNR1—pancreatic cancer	1.6e-05	0.000768	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ARG2—pancreatic cancer	1.57e-05	0.000754	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CNR1—pancreatic cancer	1.57e-05	0.000752	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—PIK3CG—pancreatic cancer	1.56e-05	0.000746	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—GCG—pancreatic cancer	1.55e-05	0.000742	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—PIK3CG—pancreatic cancer	1.52e-05	0.000729	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—GCG—pancreatic cancer	1.52e-05	0.000726	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—PIK3CD—pancreatic cancer	1.51e-05	0.000722	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—AGTR1—pancreatic cancer	1.48e-05	0.000708	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—PIK3CD—pancreatic cancer	1.47e-05	0.000706	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—STK11—pancreatic cancer	1.46e-05	0.000698	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—AGTR1—pancreatic cancer	1.45e-05	0.000692	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—STK11—pancreatic cancer	1.43e-05	0.000682	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—TYMP—pancreatic cancer	1.38e-05	0.000659	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—PIK3CD—pancreatic cancer	1.37e-05	0.000655	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—PIK3CD—pancreatic cancer	1.34e-05	0.000641	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—PIK3CB—pancreatic cancer	1.31e-05	0.000629	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GLP1R—pancreatic cancer	1.31e-05	0.000627	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—DPYD—pancreatic cancer	1.29e-05	0.000617	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—PIK3CB—pancreatic cancer	1.29e-05	0.000615	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—SMAD4—pancreatic cancer	1.28e-05	0.000611	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—CXCL8—pancreatic cancer	1.26e-05	0.000605	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—SMAD4—pancreatic cancer	1.25e-05	0.000598	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—HES1—pancreatic cancer	1.25e-05	0.000597	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—CXCL8—pancreatic cancer	1.24e-05	0.000591	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—SLC2A2—pancreatic cancer	1.22e-05	0.000585	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—HES1—pancreatic cancer	1.22e-05	0.000584	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—PIK3CB—pancreatic cancer	1.19e-05	0.000571	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—PIK3CB—pancreatic cancer	1.17e-05	0.000559	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—CXCL8—pancreatic cancer	1.15e-05	0.000549	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.14e-05	0.000544	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—CXCL8—pancreatic cancer	1.12e-05	0.000537	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GLP1R—pancreatic cancer	1.11e-05	0.000531	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—TERT—pancreatic cancer	1.09e-05	0.000523	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—DPYD—pancreatic cancer	1.09e-05	0.000523	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TERT—pancreatic cancer	1.07e-05	0.000511	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—HIF1A—pancreatic cancer	1.04e-05	0.0005	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—TSC2—pancreatic cancer	1.04e-05	0.000499	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—SLC2A2—pancreatic cancer	1.04e-05	0.000496	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.03e-05	0.000491	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—HIF1A—pancreatic cancer	1.02e-05	0.000489	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—APOE—pancreatic cancer	1.02e-05	0.000488	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TSC2—pancreatic cancer	1.02e-05	0.000488	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—KDR—pancreatic cancer	9.99e-06	0.000478	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—APOE—pancreatic cancer	9.97e-06	0.000477	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	9.89e-06	0.000474	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—KDR—pancreatic cancer	9.77e-06	0.000468	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—NFKBIA—pancreatic cancer	9.5e-06	0.000455	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CD44—pancreatic cancer	9.47e-06	0.000453	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—NOTCH1—pancreatic cancer	9.41e-06	0.00045	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—NFKBIA—pancreatic cancer	9.29e-06	0.000445	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—NOTCH1—pancreatic cancer	9.2e-06	0.000441	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PIK3CG—pancreatic cancer	9.2e-06	0.00044	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—NRAS—pancreatic cancer	9.2e-06	0.00044	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—EGF—pancreatic cancer	9.09e-06	0.000435	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GCG—pancreatic cancer	9.08e-06	0.000435	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	9.01e-06	0.000432	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PIK3CG—pancreatic cancer	9e-06	0.000431	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—NRAS—pancreatic cancer	9e-06	0.000431	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—EGF—pancreatic cancer	8.89e-06	0.000426	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—STK11—pancreatic cancer	8.54e-06	0.000409	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—EGFR—pancreatic cancer	8.38e-06	0.000401	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—EGFR—pancreatic cancer	8.2e-06	0.000393	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PIK3CD—pancreatic cancer	8.09e-06	0.000387	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CD44—pancreatic cancer	8.02e-06	0.000384	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—PIK3CA—pancreatic cancer	8.01e-06	0.000384	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—KRAS—pancreatic cancer	7.92e-06	0.000379	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PIK3CD—pancreatic cancer	7.91e-06	0.000379	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	7.86e-06	0.000376	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—PIK3CA—pancreatic cancer	7.84e-06	0.000375	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	7.78e-06	0.000373	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—KRAS—pancreatic cancer	7.74e-06	0.000371	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GCG—pancreatic cancer	7.69e-06	0.000368	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—TYMS—pancreatic cancer	7.34e-06	0.000352	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—PIK3CA—pancreatic cancer	7.27e-06	0.000348	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—STK11—pancreatic cancer	7.23e-06	0.000346	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—PIK3CA—pancreatic cancer	7.12e-06	0.000341	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PIK3CB—pancreatic cancer	7.05e-06	0.000337	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PIK3CB—pancreatic cancer	6.9e-06	0.00033	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	6.79e-06	0.000325	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CXCL8—pancreatic cancer	6.77e-06	0.000324	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—HRAS—pancreatic cancer	6.73e-06	0.000322	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CXCL8—pancreatic cancer	6.63e-06	0.000317	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—HRAS—pancreatic cancer	6.58e-06	0.000315	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—AKT1—pancreatic cancer	6.54e-06	0.000313	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CASP3—pancreatic cancer	6.48e-06	0.00031	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—AKT1—pancreatic cancer	6.4e-06	0.000306	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CASP3—pancreatic cancer	6.34e-06	0.000304	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CCND1—pancreatic cancer	6.31e-06	0.000302	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CTNNB1—pancreatic cancer	6.25e-06	0.000299	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—TYMS—pancreatic cancer	6.22e-06	0.000298	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CCND1—pancreatic cancer	6.17e-06	0.000296	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MMP9—pancreatic cancer	6.13e-06	0.000293	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CTNNB1—pancreatic cancer	6.11e-06	0.000293	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PTEN—pancreatic cancer	6.09e-06	0.000292	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MMP9—pancreatic cancer	5.99e-06	0.000287	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—APOE—pancreatic cancer	5.97e-06	0.000286	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PTEN—pancreatic cancer	5.96e-06	0.000285	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—AKT1—pancreatic cancer	5.94e-06	0.000285	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—AKT1—pancreatic cancer	5.81e-06	0.000278	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—SRC—pancreatic cancer	5.65e-06	0.00027	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—SRC—pancreatic cancer	5.53e-06	0.000265	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—VEGFA—pancreatic cancer	5.5e-06	0.000263	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—STAT3—pancreatic cancer	5.45e-06	0.000261	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—NRAS—pancreatic cancer	5.43e-06	0.00026	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	5.39e-06	0.000258	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—VEGFA—pancreatic cancer	5.38e-06	0.000258	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—STAT3—pancreatic cancer	5.33e-06	0.000255	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—NRAS—pancreatic cancer	5.32e-06	0.000255	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PPARG—pancreatic cancer	5.2e-06	0.000249	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MYC—pancreatic cancer	5.06e-06	0.000242	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—APOE—pancreatic cancer	5.06e-06	0.000242	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—TGFB1—pancreatic cancer	5.05e-06	0.000242	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MYC—pancreatic cancer	4.95e-06	0.000237	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—EGFR—pancreatic cancer	4.95e-06	0.000237	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TGFB1—pancreatic cancer	4.94e-06	0.000237	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—EGFR—pancreatic cancer	4.84e-06	0.000232	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	4.79e-06	0.000229	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	4.74e-06	0.000227	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—KRAS—pancreatic cancer	4.68e-06	0.000224	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—KRAS—pancreatic cancer	4.58e-06	0.000219	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	4.57e-06	0.000219	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PPARG—pancreatic cancer	4.41e-06	0.000211	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PIK3CA—pancreatic cancer	4.3e-06	0.000206	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PIK3CA—pancreatic cancer	4.2e-06	0.000201	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—TP53—pancreatic cancer	4.16e-06	0.000199	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	4.13e-06	0.000198	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PTGS2—pancreatic cancer	4.09e-06	0.000196	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TP53—pancreatic cancer	4.07e-06	0.000195	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	4.01e-06	0.000192	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—HRAS—pancreatic cancer	3.98e-06	0.00019	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—HRAS—pancreatic cancer	3.89e-06	0.000186	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PTEN—pancreatic cancer	3.57e-06	0.000171	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—AKT1—pancreatic cancer	3.51e-06	0.000168	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	3.5e-06	0.000168	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PTGS2—pancreatic cancer	3.47e-06	0.000166	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—AKT1—pancreatic cancer	3.43e-06	0.000164	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PTEN—pancreatic cancer	3.02e-06	0.000145	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	2.52e-06	0.000121	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	2.13e-06	0.000102	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—AKT1—pancreatic cancer	2.06e-06	9.85e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—AKT1—pancreatic cancer	1.74e-06	8.34e-05	CbGpPWpGaD
